Hemmie Chang (Past Speaker)

Hemmie Chang is Co-Chair of Foley Hoag's Life Sciences Group and Chair of its Licensing & Strategic Alliances Practice. Focusing on complex collaboration and licensing transactions, she advises both pharmaceutical and emerging biotech companies on a wide variety of licensing matters from development to commercialization. She has closed more than $10 billion in deals in recent years across diverse therapeutic areas, including representing Bridge Biotherapeutics in a collaboration and license agreement in excess of €1.1 billion with Boehringer Ingelheim, as well as Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a $650+ million collaboration peptide deal with Zealand Pharma. She has also recently represented LegoChem Bio in a $400+ million multi-target research collaboration and license agreement with Takeda Pharmaceutical Company, and LG Chem Life Sciences in a $900+ million multi-target, strategic collaboration with CUE Biopharma. Hemmie brings to the table both a strategic business perspective and legal acumen from her over two decades of experience.

She received her J.D. from Harvard Law School where she was an editor of the Harvard Law Review and her A.B. from Princeton University (Woodrow Wilson School of International and Public Affairs).